Cavendish Corporate Finance, the UK’s leading sell-side mid-market M&A firm, has advised the shareholders of Rapidscan Pharma Solutions (Rapidscan), a privately held healthcare company specialising in the production of Rapiscan®, a selective coronary vasodilator for radionuclide myocardial perfusion imaging, on its acquisition by GE Healthcare (GE), a global provider of contrast media, medical technologies and services, and biomanufacturing solutions.

GE Healthcare has acquired the exclusive rights from Rapidscan to produce and sell the pharmacological stress agent Rapiscan® (Regadenoson) in territories outside the USA, Canada and Mexico.

Cavendish Corporate Finance, which advised the shareholders of Rapidscan, has considerable experience in advising pharmaceutical and healthcare businesses. Recent high profile transactions include advising on the sale of SG Court Group to Paydens, Kent Pharmaceuticals to DCC plc and the sale of off-patent pharmaceuticals provider DB Ashbourne Ltd to Ethypharm.

Michael Jewell, the Cavendish partner who led the sale commented:

“We are delighted to have advised the shareholders of Rapidscan and to have found in GE Healthcare the right buyer to continue to expand patient access to Rapiscan® in markets outside of North America. GE Healthcare’s industry scale will drive improved access to this diagnostic tool for patients worldwide.”